FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096524676> ?p ?o ?g. }

• W3096524676 endingPage "13" @default.
• W3096524676 startingPage "1" @default.
• W3096524676 abstract "Several tests based on chemiluminescence immunoassay techniques have become available to test for SARS-CoV-2 antibodies. There is currently insufficient data on serology assay performance beyond 35 days after symptoms onset. We aimed to evaluate SARS-CoV-2 antibody tests on three widely used platforms. A chemiluminescent microparticle immunoassay (CMIA; Abbott Diagnostics, USA), a luminescence immunoassay (LIA; Diasorin, Italy), and an electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics, Switzerland) were investigated. In a multigroup study, sensitivity was assessed in a group of participants with confirmed SARS-CoV-2 ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>n</mi> <mo>=</mo> <mn>145</mn> </math> ), whereas specificity was determined in two groups of participants without evidence of COVID-19 (i.e., healthy blood donors, <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>n</mi> <mo>=</mo> <mn>191</mn> </math> , and healthcare workers, <math xmlns=http://www.w3.org/1998/Math/MathML id=M3> <mi>n</mi> <mo>=</mo> <mn>1002</mn> </math> ). Receiver operating characteristic (ROC) curves, multilevel likelihood ratios (LR), and positive (PPV) and negative (NPV) predictive values were characterized. Finally, analytical specificity was characterized in samples with evidence of the Epstein–Barr virus (EBV) ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M4> <mi>n</mi> <mo>=</mo> <mn>9</mn> </math> ), cytomegalovirus (CMV) ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M5> <mi>n</mi> <mo>=</mo> <mn>7</mn> </math> ), and endemic common-cold coronavirus infections ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M6> <mi>n</mi> <mo>=</mo> <mn>12</mn> </math> ) taken prior to the current SARS-CoV-2 pandemic. The diagnostic accuracy was comparable in all three assays (AUC 0.98). Using the manufacturers’ cut-offs, the sensitivities were 90%, 95% confidence interval [84,94] (LIA), 93% [88,96] (CMIA), and 96% [91,98] (ECLIA). The specificities were 99.5% [98.9,99.8] (CMIA), 99.7% [99.3,99.9] (LIA), and 99.9% [99.5,99.98] (ECLIA). The LR at half of the manufacturers’ cut-offs were 60 (CMIA), 82 (LIA), and 575 (ECLIA) for positive and 0.043 (CMIA) and 0.035 (LIA, ECLIA) for negative results. ECLIA had higher PPV at low pretest probabilities than CMIA and LIA. No interference with EBV or CMV infection was observed, whereas endemic coronavirus in some cases provided signals in LIA and/or CMIA. Although the diagnostic accuracy of the three investigated assays is comparable, their performance in low-prevalence settings is different. Introducing gray zones at half of the manufacturers’ cut-offs is suggested, especially for orthogonal testing approaches that use a second assay for confirmation." @default.
• W3096524676 created "2020-11-09" @default.
• W3096524676 creator A5001151283 @default.
• W3096524676 creator A5006353290 @default.
• W3096524676 creator A5015236866 @default.
• W3096524676 creator A5020708921 @default.
• W3096524676 creator A5026815801 @default.
• W3096524676 creator A5026846457 @default.
• W3096524676 creator A5030101128 @default.
• W3096524676 creator A5033177889 @default.
• W3096524676 creator A5042203220 @default.
• W3096524676 creator A5042732930 @default.
• W3096524676 creator A5043952542 @default.
• W3096524676 creator A5052883101 @default.
• W3096524676 creator A5053003825 @default.
• W3096524676 creator A5061951180 @default.
• W3096524676 creator A5065398070 @default.
• W3096524676 creator A5065738420 @default.
• W3096524676 creator A5076689872 @default.
• W3096524676 creator A5077178350 @default.
• W3096524676 creator A5077744708 @default.
• W3096524676 creator A5080523158 @default.
• W3096524676 creator A5084754410 @default.
• W3096524676 creator A5086815077 @default.
• W3096524676 creator A5088324762 @default.
• W3096524676 creator A5091458689 @default.
• W3096524676 date "2021-01-06" @default.
• W3096524676 modified "2023-10-08" @default.
• W3096524676 title "Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies" @default.
• W3096524676 cites W1987863732 @default.
• W3096524676 cites W1991771021 @default.
• W3096524676 cites W2087762289 @default.
• W3096524676 cites W2151287133 @default.
• W3096524676 cites W3008827533 @default.
• W3096524676 cites W3010719113 @default.
• W3096524676 cites W3012364352 @default.
• W3096524676 cites W3012751338 @default.
• W3096524676 cites W3012756997 @default.
• W3096524676 cites W3012846954 @default.
• W3096524676 cites W3013013352 @default.
• W3096524676 cites W3014249391 @default.
• W3096524676 cites W3014721277 @default.
• W3096524676 cites W3016214835 @default.
• W3096524676 cites W3016391040 @default.
• W3096524676 cites W3016484923 @default.
• W3096524676 cites W3016586571 @default.
• W3096524676 cites W3017196735 @default.
• W3096524676 cites W3017216935 @default.
• W3096524676 cites W3017325113 @default.
• W3096524676 cites W3017576620 @default.
• W3096524676 cites W3020654962 @default.
• W3096524676 cites W3020992444 @default.
• W3096524676 cites W3021039517 @default.
• W3096524676 cites W3021590963 @default.
• W3096524676 cites W3021973602 @default.
• W3096524676 cites W3022156496 @default.
• W3096524676 cites W3022276126 @default.
• W3096524676 cites W3022435581 @default.
• W3096524676 cites W3023710859 @default.
• W3096524676 cites W3023897783 @default.
• W3096524676 cites W3024554369 @default.
• W3096524676 cites W3030877763 @default.
• W3096524676 cites W3033175757 @default.
• W3096524676 cites W3033484283 @default.
• W3096524676 cites W3035172419 @default.
• W3096524676 cites W3035189381 @default.
• W3096524676 cites W3037170999 @default.
• W3096524676 cites W3037622635 @default.
• W3096524676 cites W3038010908 @default.
• W3096524676 cites W3047764989 @default.
• W3096524676 cites W3081891801 @default.
• W3096524676 cites W3092512024 @default.
• W3096524676 cites W3094110746 @default.
• W3096524676 cites W3094136275 @default.
• W3096524676 cites W3096867322 @default.
• W3096524676 cites W4205829018 @default.
• W3096524676 doi "https://doi.org/10.1155/2021/8810196" @default.
• W3096524676 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7834819" @default.
• W3096524676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33532006" @default.
• W3096524676 hasPublicationYear "2021" @default.
• W3096524676 type Work @default.
• W3096524676 sameAs 3096524676 @default.
• W3096524676 citedByCount "15" @default.
• W3096524676 countsByYear W30965246762021 @default.
• W3096524676 countsByYear W30965246762022 @default.
• W3096524676 countsByYear W30965246762023 @default.
• W3096524676 crossrefType "journal-article" @default.
• W3096524676 hasAuthorship W3096524676A5001151283 @default.
• W3096524676 hasAuthorship W3096524676A5006353290 @default.
• W3096524676 hasAuthorship W3096524676A5015236866 @default.
• W3096524676 hasAuthorship W3096524676A5020708921 @default.
• W3096524676 hasAuthorship W3096524676A5026815801 @default.
• W3096524676 hasAuthorship W3096524676A5026846457 @default.
• W3096524676 hasAuthorship W3096524676A5030101128 @default.
• W3096524676 hasAuthorship W3096524676A5033177889 @default.
• W3096524676 hasAuthorship W3096524676A5042203220 @default.
• W3096524676 hasAuthorship W3096524676A5042732930 @default.
• W3096524676 hasAuthorship W3096524676A5043952542 @default.

• next